Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 3.81B P/E - EPS this Y - Ern Qtrly Grth -
Income -342.31M Forward P/E -10.54 EPS next Y - 50D Avg Chg 1.00%
Sales 1.01M PEG - EPS past 5Y - 200D Avg Chg 63.00%
Dividend N/A Price/Book 4.78 EPS next 5Y - 52W High Chg -8.00%
Recommedations 3.00 Quick Ratio 16.56 Shares Outstanding 50.07M 52W Low Chg 220.00%
Insider Own 0.70% ROA -22.13% Shares Float 48.20M Beta -0.19
Inst Own 92.52% ROE -36.80% Shares Shorted/Prior 2.14M/2.86M Price 76.01
Gross Margin 100.00% Profit Margin - Avg. Volume 1,897,877 Target Price 71.50
Oper. Margin -34,185.81% Earnings Date Nov 7 Volume 2,843,392 Change 0.00%
Turning Point Therapeutics, Inc News
08/16/22 Bristol Myers Squibb and Turning Point Therapeutics Announce Expiration of HSR Act Waiting Period and Clearance from Federal Cartel Office of Germany Related to Pending Acquisition of Turning Point Therapeutics
08/08/22 Turning Point Therapeutics Reports Second-Quarter 2022 Financial Results, Provides Operational Updates
07/27/22 Turning Point Therapeutics Provides Regulatory Update for Repotrectinib for the Treatment of ROS1+ Advanced NSCLC
07/27/22 Bristol Myers Squibb (BMY) Q2 2022 Earnings Call Transcript
07/25/22 Bristol-Myers (BMY) to Post Q2 Earnings: What is in the Cards?
07/21/22 How These Acquisitions Are Changing the Outlook for Bristol Myers Squibb
06/24/22 Turning Point Therapeutics and MD Anderson Announce Strategic Alliance to Advance Precision Cancer Therapies
06/22/22 IBD Stock Of The Day: Bristol Myers Eyes Breakout After $4.1 Billion Buyout
06/09/22 The Zacks Analyst Blog Highlights Bristol Myers, Turning Point Therapeutics, Regeneron, Novavax, and Mirati Therapeutics
06/08/22 Biotech Stock Roundup: BMY's Acquisition, REGN to Buy Libtayo & More
06/06/22 Bristol Myers (BMY) to Acquire Turning Point, Withdraws sBLA
06/03/22 Bristol Myers Snaps Up Turning Point For $4.1 Billion In Cash β€” Is The Biotech Bear Dead?
06/03/22 Bristol Myers Squibb buying lung-cancer-focused Turning Point for $4.1 billion
06/03/22 Bristol Myers to Buy Turning Point Therapeutics in $4.1 Billion Oncology Deal
06/03/22 UPDATE 2-Bristol Myers to buy Turning Point Therapeutics for $4.1 bln
06/03/22 Bristol Myers boosts cancer drug portfolio with $4.1 billion Turning Point deal
06/03/22 Bristol Myers Squibb Announces $4.1B Deal for Turning Point Therapeutics
03:30 PM Turning Point Therapeutics to Participate in Upcoming Investor Conferences
05/16/22 Turning Point Therapeutics Announces Appointment of Steve Sabus as Chief Commercial Officer

Turning Point Therapeutics, Inc., a clinical-stage precision oncology biopharmaceutical company, engages in designing and developing therapies that target genetic drivers of cancer. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naΓ―ve and TKI-pretreated patients. The company's lead drug candidate repotrectinib is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+ and NTRK+ advanced solid tumors. It also develops TPX-0022, a MET/SRC/CSF1R inhibitor, which is in Phase 1 SHIELD-1 clinical trial for patients with advanced solid tumors harboring genetic alterations in MET; TPX-0046, a RET inhibitor that is in 1/2 SWORD-1 clinical trial for patients with advanced solid tumors harboring RET genetic alterations; and TPX-0131, an ALK inhibitor, which is in Phase 1/2 FORGE-1 study for patient with advanced or metastatic TKI-pretreated ALK-positive NSCLC. Turning Point Therapeutics, Inc. was founded in 2013 and is headquartered in San Diego, California. As of August 15, 2022, Turning Point Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company.

TPTX Chatroom

User Image Power2k Posted - 5 days ago

$SAVA BMS bought a tiny biotech $TPTX for $4.1b this June even though the oncology market is so crowded and satuated. Who is buying SAVA for $41b in a much more vacant Alz market with essentially NO SINGLE effective drug yet? $PFE or $LLY?

User Image bigwhalealert Posted - 2 weeks ago

$TPTX BUY/SELL METER Alert Cross 1% +- Technical Analysis https://t8sk.com/TPTX

User Image Joyloon Posted - 08/30/22

$CRDF Just seen a another story of BP buying mid-stage biotech in the cancer/KRAS space: $TPTX aquired by $BMY for ~ 3B. Mainly for their relatively broad kinase inhibitor Repotrectinib. https://news.bms.com/news/details/2022/Bristol-Myers-Squibb-to-Acquire-Turning-Point-Therapeutics-a-Leading-Precision-Oncology-Company/default.aspx Could happen anytime to $CRDF or $VSTM and provides a rough estimation of valuation in this space

User Image cctranscripts Posted - 08/29/22

Securities registration termination [Section 12(g)] https://www.conferencecalltranscripts.com/summary/?id=11243735 $TPTX

User Image risenhoover Posted - 08/29/22

$TPTX / Turning Point Therapeutics files form 15-12G https://fintel.io/sf/us/tptx?utm_source=stocktwits.com&utm_medium=Referral&utm_campaign=filing

User Image fla Posted - 08/29/22

$TPTX [15s. delayed] filed form 15-12G on August 29, 16:30:18 https://s.flashalert.me/UoRpJZ

User Image Quantisnow Posted - 08/29/22

$TPTX πŸ“œ SEC Form 15-12G filed by Turning Point Therapeutics Inc. https://quantisnow.com/i/3349053?utm_source=stocktwits 45 seconds delayed.

User Image Newsfilter Posted - 08/29/22

$TPTX Form 15-12G (securities registration termination [section 12(g)]) filed with the SEC https://newsfilter.io/a/3853472a41cebcdf7363b51fd2377bc3

User Image ChartMill Posted - 1 month ago

$TPTX was analyzed by 15 analysts. The buy consensus is at 72%. So analysts seem to be mildly confident about $TPTX. https://www.chartmill.com/stock/analyzer/stock/TPTX?view=analyst-ratings&utm_source=stocktwits&utm_medium=ANALYST&utm_content=TPTX&utm_campaign=social_tracking

User Image Quantisnow Posted - 1 month ago

$TPTX πŸ“œ SEC Form EFFECT filed by Turning Point Therapeutics Inc. https://quantisnow.com/i/3319122?utm_source=stocktwits 45 seconds delayed.

User Image fla Posted - 1 month ago

$TPTX [15s. delayed] filed form EFFECT on August 23, 00:15:10 https://s.flashalert.me/8xaW3

User Image Newsfilter Posted - 1 month ago

$TPTX Form EFFECT (notice of effectiveness) filed with the SEC https://newsfilter.io/a/882568c401ca673c4940fef7ff82055e

User Image tickeron Posted - 1 month ago

The market looks weird..Do not be too greedy today! $TPTX in +0.81% Uptrend, growing for three consecutive days on August 16, 2022. View odds for this and other indicators: https://srnk.us/go/3927215

User Image Newsfilter Posted - 1 month ago

$TPTX reported 3 new insider trades to the SEC in the last 2 minutes. Nicholson Garry A (Director) sold new securities https://newsfilter.io/articles/4-form-f933d4868cbf6d5a4d4bcaf4a8c8e583 Machado Patrick (Director) sold new securities https://newsfilter.io/articles/4-form-6ff763a0d54113fadbabf85aedba48e3 $171,278,160.00 of shares sold by George Simeon (Director) https://newsfilter.io/articles/4-form-8c5e23ee7c240c817de6831cf14ca33a

User Image fla Posted - 1 month ago

$TPTX [15s. delayed] filed SEC form 4: Director Nicholson Garry A: Transacted Derivative Securities between 2022-08-17 and 2022-08-17. https://s.flashalert.me/7tPan

User Image fla Posted - 1 month ago

$TPTX [15s. delayed] filed SEC form 4: Director George Simeon: Disposed 2,253,660 of Common Stock at price $76 on 2022-08-17, decreased h https://s.flashalert.me/2drtL

User Image fla Posted - 1 month ago

$TPTX [15s. delayed] filed SEC form 4: Director Gallagher Carol Giltner: Transacted Derivative Securities between 2022-08-17 and 2022-08- https://s.flashalert.me/j3T3d

User Image Newsfilter Posted - 1 month ago

$TPTX Form 4 (statement of changes in beneficial ownership of securities) filed with the SEC https://newsfilter.io/a/172fe3bd61e119c28dbfbfc182305cfe

User Image Newsfilter Posted - 1 month ago

$TPTX reported 2 new insider trades to the SEC in the last 2 minutes. $152,000.00 of shares sold by Alles Mark J (Director) https://newsfilter.io/articles/4-form-19605929ac8169097798b73256da7dd0 14,995 shares sold by Bodem Barbara W. (Director) https://newsfilter.io/articles/4-form-41c51a0d35721186e2d0d926a6feb4ca

User Image fla Posted - 1 month ago

$TPTX [15s. delayed] filed SEC form 4: Director Bodem Barbara W.: Transacted Derivative Securities on 2022-08-17. https://s.flashalert.me/4Cvgii

User Image fla Posted - 1 month ago

$TPTX [15s. delayed] filed SEC form 4: Director Alles Mark J: Disposed 2,000 of Common Stock at price $76 on 2022-08-17, decreased holdin https://s.flashalert.me/yjdLQ

User Image fla Posted - 1 month ago

$TPTX [15s. delayed] filed SEC form 4: EVP & Chief Financial Officer TOMBESI PAOLO: Disposed 29,778 of Common Stock at price $76 on 2022- https://s.flashalert.me/VbeE5

User Image Newsfilter Posted - 1 month ago

$TPTX Form 4 (statement of changes in beneficial ownership of securities) filed with the SEC https://newsfilter.io/a/2bb2cdf320ee9fe33de90948fcdf2549

User Image Newsfilter Posted - 1 month ago

$TPTX reported 3 new insider trades to the SEC in the last 2 minutes. $3,420,000.00 of shares sold by Sun Brian (SVP & General Counsel) https://newsfilter.io/articles/4-form-ef156eb7bd32fb7b44027fa2f0521910 $3,137,584.00 of shares sold by Hirmand Mohammad (EVP and Chief Medical Officer) https://newsfilter.io/articles/4-form-36d780d0279a184b347559ce5f14f1a0 $2,786,692.00 of shares sold by Sabus Steve M (SVP & Chief Commercial Officer) https://newsfilter.io/articles/4-form-f7de1bff816f760edc871560fc88b9f3

User Image fla Posted - 1 month ago

$TPTX [15s. delayed] filed SEC form 4: SVP & Chief Commercial Officer Sabus Steve M: Disposed 36,667 of Common Stock at price $76 on 2022 https://s.flashalert.me/7YU2Om

User Image fla Posted - 1 month ago

$TPTX [15s. delayed] filed SEC form 4: EVP and Chief Medical Officer Hirmand Mohammad: Disposed 41,284 of Common Stock at price $76 on 20 https://s.flashalert.me/Vyx6d

User Image Quantisnow Posted - 1 month ago

$TPTX πŸ“œ SEC Form 4: Countouriotis Athena returned $8,432,884 worth of shares to the company (110,959 units at $76.00), closing all direct ownership in the company (withholding tax) https://quantisnow.com/i/3302037?utm_source=stocktwits 45 seconds delayed.

User Image fla Posted - 1 month ago

$TPTX [15s. delayed] filed SEC form 4: President & CEO Countouriotis Athena: Disposed 110,959 of Common Stock at price $76 on 2022-08-17, https://s.flashalert.me/7RHtl

User Image Newsfilter Posted - 1 month ago

$TPTX Form 4 (statement of changes in beneficial ownership of securities) filed with the SEC https://newsfilter.io/a/44a439ecfeb811c04ce1ad4558dfb648

User Image BidaskBot Posted - 1 month ago

TurningPointTherapeutics $TPTX BidaskScore is Downgraded to Sold https://bidaskclub.com/news/company/2022-08-16/TPTX

Analyst Ratings
SVB Leerink Market Perform Jun 13, 22
Cowen & Co. Market Perform Jun 6, 22
HC Wainwright & Co. Neutral Jun 6, 22
Wedbush Neutral Jun 3, 22
Goldman Sachs Buy May 24, 22
B of A Securities Buy May 20, 22
SVB Leerink Outperform May 11, 22
HC Wainwright & Co. Buy Mar 22, 22
Stifel Hold Mar 1, 22
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Reich Siegfried EVP & Chief Scientif.. EVP & Chief Scientific Officer Feb 09 Sell 36.3 397 14,411 3,448 02/11/22
Partridge Andrew John EVP & Chief Commerci.. EVP & Chief Commercial Officer Feb 09 Sell 36.3 221 8,022 22,078 02/11/22
North Annette EVP & General Counse.. EVP & General Counsel Feb 09 Sell 36.3 669 24,285 11,696 02/11/22
Hirmand Mohammad EVP & Chief Medical.. EVP & Chief Medical Officer Feb 09 Sell 36.3 669 24,285 6,838 02/11/22
Countouriotis Athena President & CEO President & CEO Feb 09 Sell 36.3 2,971 107,847 47,930 02/11/22
North Annette EVP, General Counsel.. EVP, General Counsel & Secty. Aug 31 Sell 80 10,000 800,000 12,365 08/31/21
North Annette EVP, General Counsel.. EVP, General Counsel & Secty. Aug 31 Option 17 10,000 170,000 22,365 08/31/21
Baker Brian Lee SVP of Finance and A.. SVP of Finance and Admin. Mar 24 Option 4.49 28,435 127,673 32,551 03/24/21
Baker Brian Lee SVP of Finance and A.. SVP of Finance and Admin. Mar 24 Sell 100.99 28,435 2,871,651 4,116 03/24/21
Reich Siegfried EVP & Chief Scientif.. EVP & Chief Scientific Officer Mar 05 Sell 106.52 35,550 3,786,786 3,845 03/05/21
Reich Siegfried EVP & Chief Scientif.. EVP & Chief Scientific Officer Mar 05 Option 51.28 35,550 1,823,004 39,395 03/05/21
Countouriotis Athena President & CEO President & CEO Feb 11 Option 3.2 60,000 192,000 59,137 02/11/21
Countouriotis Athena President & CEO President & CEO Feb 11 Sell 137.48 60,000 8,248,800 50,195 02/11/21
North Annette EVP, General Counsel.. EVP, General Counsel & Secty. Feb 02 Option 17 25,000 425,000 9,016 02/02/21
North Annette EVP, General Counsel.. EVP, General Counsel & Secty. Feb 02 Sell 127.14 25,000 3,178,500 02/02/21
Larson Yi EVP & Chief Financia.. EVP & Chief Financial Officer Feb 02 Option 54.03 30,000 1,620,900 17,002 02/02/21
Larson Yi EVP & Chief Financia.. EVP & Chief Financial Officer Feb 02 Sell 127.27 30,000 3,818,100 2,704 02/02/21
Baker Brian Lee SVP of Finance and A.. SVP of Finance and Admin. Jan 08 Option 4.49 28,438 127,687 32,246 01/08/21
Baker Brian Lee SVP of Finance and A.. SVP of Finance and Admin. Jan 08 Sell 121.97 31,238 3,810,099 1,008 01/08/21
Hirmand Mohammad EVP and Chief Medica.. EVP and Chief Medical Officer Jan 05 Option 54.73 10,000 547,300 1,537 01/05/21
Hirmand Mohammad EVP and Chief Medica.. EVP and Chief Medical Officer Jan 05 Sell 120.95 10,300 1,245,785 284 01/05/21